Auto-generated from public data. Not the firm's stated position.
Droia Ventures appears to focus on clinical-stage and growth-phase biotech and healthtech companies, with a particular emphasis on therapeutic innovation in oncology, neurodegeneration, and protein-based drug development. Based on disclosed portfolio data, the firm deploys check sizes starting at approximately €3.0M and concentrates on Series A through growth-stage investments in Europe.
Generated 10 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Auto-detected from Droia Ventures's website.
PhD in Genetics from University of Wisconsin-Madison with experience at Novartis, Celgene, and Arch Venture Partners.
Pharm.D. from University of Leuven with MBA from Vlerick Management School and experience at McKinsey, Arthur D. Little, TiGenix, Prosensa, and Tusk Therapeutics.
M.Sc. Bioengineering from KU Leuven, PhD in Bioengineering with experience in antimicrobial and cystic fibrosis drug development.
M.Sc. Bio-Engineering from University of Leuven with experience at Arthur D. Little and seasoned biotech investor.
BA in Biology from University of Virginia, PhD in Genetics from University of Wisconsin-Madison, founder of Anti Cancer Fund.
PhD in Biomedical Sciences from University of Leuven with doctoral research in angiogenesis and vascular metabolism.
M.Sc. Biomedical Sciences and PhD in Tumor Immunology from University of Leuven with pharmaceutical sciences expertise.
BA in Biochemistry from Catholic University in Chile, PhD in Cell Biology from UCSF with experience at Medivation and Praxis Biotech.
PhD in Molecular Biology from TIFR Mumbai, trained at Yale, NIH, and Harvard in RNA metabolism and immunology.
Focus and check size from the firm's website. Website reachable as of Sept 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.